Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.

Novo Nordisk B

Novo Nordisk B

311,70DKK
+1,93% (+5,90)
Tänään 
Ylin312,85
Alin307,80
Vaihto
341 MDKK
311,70DKK
+1,93% (+5,90)
Tänään 
Ylin312,85
Alin307,80
Vaihto
341 MDKK

Novo Nordisk B

Novo Nordisk B

311,70DKK
+1,93% (+5,90)
Tänään 
Ylin312,85
Alin307,80
Vaihto
341 MDKK
311,70DKK
+1,93% (+5,90)
Tänään 
Ylin312,85
Alin307,80
Vaihto
341 MDKK

Novo Nordisk B

Novo Nordisk B

311,70DKK
+1,93% (+5,90)
Tänään 
Ylin312,85
Alin307,80
Vaihto
341 MDKK
311,70DKK
+1,93% (+5,90)
Tänään 
Ylin312,85
Alin307,80
Vaihto
341 MDKK
2025 Q3 -tulosraportti
29 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,81 %Tuotto/v

Tarjoustasot

DenmarkNasdaq Copenhagen
Määrä
Osto
227
Myynti
Määrä
401

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
168--
68--
69--
168--
51--
Ylin
312,85
VWAP
310,57
Alin
307,8
VaihtoMäärä
341 1 098 109
VWAP
310,57
Ylin
312,85
Alin
307,8
VaihtoMäärä
341 1 098 109

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Ostaneet eniten

Ostaneet eniten
VälittäjäOstettuMyytyNettoSisäinen
Anonyymi1 161 7641 161 76400

Myyneet eniten

Myyneet eniten
VälittäjäOstettuMyytyNettoSisäinen
Anonyymi1 161 7641 161 76400

Yhtiötapahtumat

Seuraava tapahtuma
2025 Q4 -tulosraportti
4.2.2026
Menneet tapahtumat
Ylimääräinen yhtiökokous 202514.11.
2025 Q3 -tulosraportti6.11.
2025 Q3 -tulosraportti5.11.
2025 Q2 -tulosraportti7.8.
2025 Q2 -tulosraportti6.8.
Datan lähde: Quartr, FactSet

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 24 min sitten
    ·
    24 min sitten
    ·
    Eli Lilly is going down, Novo is going up.. Is it about to turn?
    18 min sitten
    ·
    18 min sitten
    ·
    LLY has risen 35% after the earnings report. Novo has fallen 3% since their earnings report. I just think there is profit-taking in LLY. There isn't much profit-taking in Novo....................
  • 32 min sitten
    ·
    32 min sitten
    ·
    Does anyone know where Nordnet gets their forward P/E from? I'm looking at 2027 where it's estimated at 12.45, it's currently at 13.11. Does this mean that earnings are only expected to increase by 3% from the current estimated 2025 earnings over the next 2 years? Has Novo itself announced this?
    21 min sitten
    ·
    21 min sitten
    ·
    No, that's not something Novo announces, it's typically compiled as an average of analysts' expectations, but which analysts they base the figure on remains unknown.
  • 30 min sitten · Muokattu
    ·
    30 min sitten · Muokattu
    ·
    It's quite wild that Novo's communication strategy simply consists of talking the stock down as much as possible: "The financial institution Berenberg writes this, after a meeting with CFO Karsten Munk Knudsen." "The CFO has reiterated to Berenberg the many headwinds that the pharmaceutical giant faces in 2026." Excuse me, but I have never experienced anything like it.
    27 min sitten · Muokattu
    ·
    27 min sitten · Muokattu
    ·
    I perceive KK as an accounting nerd who doesn't have a clue how to act professionally in relation to analysts and investors. He thinks he should be as "honest" as possible, but the problem is that he doesn't even know how sales will develop in 2026. Of course, he shouldn't say anything about that either, but maybe he should just keep his mouth shut about what he believes from his nerd perspective, and then Novo should let the CEO speak. Then we might also hear something about the CEO's work to get sales going.
  • 44 min sitten
    ·
    44 min sitten
    ·
    All analysts' estimates are based on one key factor that is absolutely crucial for where they set their price targets, and that key factor is subjective (and adjusted to today's price, so the busy analyst doesn't stand out too much IMO). One thing is that analysts calculate and guess future sales and costs, another thing is then what value they believe it should have in relation to the P/E ratio. It is absolutely given that this key factor is very different between Novo Nordisk and Eli Lilly, for example. One can talk at length about Eli Lilly's merits, but fundamentally, the key factor is based on free imagination and the analyst's own personal opinion, not on facts, because there are no facts about what the future looks like. Analysts with low price targets will defend their key values for Lilly and Novo respectively by arguing that they do not believe Novo will grow in the next couple of years (at least not next year), and therefore the key factor must be much lower for Novo than for Lilly, but we all know how much sentiment in the stock market matters, and it only takes a small shift in sentiment for prices to move quite dramatically. I still hold my Novo shares.
    25 min sitten
    ·
    25 min sitten
    ·
    Fundamentally, analysts' price targets mean nothing; the 'real' numbers will eventually come to light, so one doesn't need to be so nervous about whether they are right or wrong. If one reads along here, one quickly gets the impression that analysts are some of the most fact-resistant, incompetent, and manipulative people there are.
    12 min sitten · Muokattu
    ·
    12 min sitten · Muokattu
    ·
    Novo itself has enormous problems getting its guidance right. The last couple of times, the market has downgraded Novo's guidance before the company itself did. A little worrying. Analysts are actually fantastically competent, here, given what their targets are.
  • 51 min sitten
    ·
    51 min sitten
    ·
    Have you sold at a loss for tax deduction? The rest of us want to go north.
    8 min sitten · Muokattu
    ·
    8 min sitten · Muokattu
    ·
    That sounds great with deductions! You get no deduction, you merely stand in minus with SKAT until you are again in plus and have a surplus.
    7 min sitten
    ·
    7 min sitten
    ·
    It is also a deduction. Even the tax authority's website calls it a “deduction for loss on shares”.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset ja analyysit

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q3 -tulosraportti
29 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,81 %Tuotto/v

Uutiset ja analyysit

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 24 min sitten
    ·
    24 min sitten
    ·
    Eli Lilly is going down, Novo is going up.. Is it about to turn?
    18 min sitten
    ·
    18 min sitten
    ·
    LLY has risen 35% after the earnings report. Novo has fallen 3% since their earnings report. I just think there is profit-taking in LLY. There isn't much profit-taking in Novo....................
  • 32 min sitten
    ·
    32 min sitten
    ·
    Does anyone know where Nordnet gets their forward P/E from? I'm looking at 2027 where it's estimated at 12.45, it's currently at 13.11. Does this mean that earnings are only expected to increase by 3% from the current estimated 2025 earnings over the next 2 years? Has Novo itself announced this?
    21 min sitten
    ·
    21 min sitten
    ·
    No, that's not something Novo announces, it's typically compiled as an average of analysts' expectations, but which analysts they base the figure on remains unknown.
  • 30 min sitten · Muokattu
    ·
    30 min sitten · Muokattu
    ·
    It's quite wild that Novo's communication strategy simply consists of talking the stock down as much as possible: "The financial institution Berenberg writes this, after a meeting with CFO Karsten Munk Knudsen." "The CFO has reiterated to Berenberg the many headwinds that the pharmaceutical giant faces in 2026." Excuse me, but I have never experienced anything like it.
    27 min sitten · Muokattu
    ·
    27 min sitten · Muokattu
    ·
    I perceive KK as an accounting nerd who doesn't have a clue how to act professionally in relation to analysts and investors. He thinks he should be as "honest" as possible, but the problem is that he doesn't even know how sales will develop in 2026. Of course, he shouldn't say anything about that either, but maybe he should just keep his mouth shut about what he believes from his nerd perspective, and then Novo should let the CEO speak. Then we might also hear something about the CEO's work to get sales going.
  • 44 min sitten
    ·
    44 min sitten
    ·
    All analysts' estimates are based on one key factor that is absolutely crucial for where they set their price targets, and that key factor is subjective (and adjusted to today's price, so the busy analyst doesn't stand out too much IMO). One thing is that analysts calculate and guess future sales and costs, another thing is then what value they believe it should have in relation to the P/E ratio. It is absolutely given that this key factor is very different between Novo Nordisk and Eli Lilly, for example. One can talk at length about Eli Lilly's merits, but fundamentally, the key factor is based on free imagination and the analyst's own personal opinion, not on facts, because there are no facts about what the future looks like. Analysts with low price targets will defend their key values for Lilly and Novo respectively by arguing that they do not believe Novo will grow in the next couple of years (at least not next year), and therefore the key factor must be much lower for Novo than for Lilly, but we all know how much sentiment in the stock market matters, and it only takes a small shift in sentiment for prices to move quite dramatically. I still hold my Novo shares.
    25 min sitten
    ·
    25 min sitten
    ·
    Fundamentally, analysts' price targets mean nothing; the 'real' numbers will eventually come to light, so one doesn't need to be so nervous about whether they are right or wrong. If one reads along here, one quickly gets the impression that analysts are some of the most fact-resistant, incompetent, and manipulative people there are.
    12 min sitten · Muokattu
    ·
    12 min sitten · Muokattu
    ·
    Novo itself has enormous problems getting its guidance right. The last couple of times, the market has downgraded Novo's guidance before the company itself did. A little worrying. Analysts are actually fantastically competent, here, given what their targets are.
  • 51 min sitten
    ·
    51 min sitten
    ·
    Have you sold at a loss for tax deduction? The rest of us want to go north.
    8 min sitten · Muokattu
    ·
    8 min sitten · Muokattu
    ·
    That sounds great with deductions! You get no deduction, you merely stand in minus with SKAT until you are again in plus and have a surplus.
    7 min sitten
    ·
    7 min sitten
    ·
    It is also a deduction. Even the tax authority's website calls it a “deduction for loss on shares”.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

DenmarkNasdaq Copenhagen
Määrä
Osto
227
Myynti
Määrä
401

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
168--
68--
69--
168--
51--
Ylin
312,85
VWAP
310,57
Alin
307,8
VaihtoMäärä
341 1 098 109
VWAP
310,57
Ylin
312,85
Alin
307,8
VaihtoMäärä
341 1 098 109

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Ostaneet eniten

Ostaneet eniten
VälittäjäOstettuMyytyNettoSisäinen
Anonyymi1 161 7641 161 76400

Myyneet eniten

Myyneet eniten
VälittäjäOstettuMyytyNettoSisäinen
Anonyymi1 161 7641 161 76400

Yhtiötapahtumat

Seuraava tapahtuma
2025 Q4 -tulosraportti
4.2.2026
Menneet tapahtumat
Ylimääräinen yhtiökokous 202514.11.
2025 Q3 -tulosraportti6.11.
2025 Q3 -tulosraportti5.11.
2025 Q2 -tulosraportti7.8.
2025 Q2 -tulosraportti6.8.
Datan lähde: Quartr, FactSet

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q3 -tulosraportti
29 päivää sitten54 min

Uutiset ja analyysit

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Seuraava tapahtuma
2025 Q4 -tulosraportti
4.2.2026
Menneet tapahtumat
Ylimääräinen yhtiökokous 202514.11.
2025 Q3 -tulosraportti6.11.
2025 Q3 -tulosraportti5.11.
2025 Q2 -tulosraportti7.8.
2025 Q2 -tulosraportti6.8.
Datan lähde: Quartr, FactSet

Tuotteita joiden kohde-etuutena tämä arvopaperi

3,75 DKK/osake
Viimeisin osinko
3,81 %Tuotto/v

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 24 min sitten
    ·
    24 min sitten
    ·
    Eli Lilly is going down, Novo is going up.. Is it about to turn?
    18 min sitten
    ·
    18 min sitten
    ·
    LLY has risen 35% after the earnings report. Novo has fallen 3% since their earnings report. I just think there is profit-taking in LLY. There isn't much profit-taking in Novo....................
  • 32 min sitten
    ·
    32 min sitten
    ·
    Does anyone know where Nordnet gets their forward P/E from? I'm looking at 2027 where it's estimated at 12.45, it's currently at 13.11. Does this mean that earnings are only expected to increase by 3% from the current estimated 2025 earnings over the next 2 years? Has Novo itself announced this?
    21 min sitten
    ·
    21 min sitten
    ·
    No, that's not something Novo announces, it's typically compiled as an average of analysts' expectations, but which analysts they base the figure on remains unknown.
  • 30 min sitten · Muokattu
    ·
    30 min sitten · Muokattu
    ·
    It's quite wild that Novo's communication strategy simply consists of talking the stock down as much as possible: "The financial institution Berenberg writes this, after a meeting with CFO Karsten Munk Knudsen." "The CFO has reiterated to Berenberg the many headwinds that the pharmaceutical giant faces in 2026." Excuse me, but I have never experienced anything like it.
    27 min sitten · Muokattu
    ·
    27 min sitten · Muokattu
    ·
    I perceive KK as an accounting nerd who doesn't have a clue how to act professionally in relation to analysts and investors. He thinks he should be as "honest" as possible, but the problem is that he doesn't even know how sales will develop in 2026. Of course, he shouldn't say anything about that either, but maybe he should just keep his mouth shut about what he believes from his nerd perspective, and then Novo should let the CEO speak. Then we might also hear something about the CEO's work to get sales going.
  • 44 min sitten
    ·
    44 min sitten
    ·
    All analysts' estimates are based on one key factor that is absolutely crucial for where they set their price targets, and that key factor is subjective (and adjusted to today's price, so the busy analyst doesn't stand out too much IMO). One thing is that analysts calculate and guess future sales and costs, another thing is then what value they believe it should have in relation to the P/E ratio. It is absolutely given that this key factor is very different between Novo Nordisk and Eli Lilly, for example. One can talk at length about Eli Lilly's merits, but fundamentally, the key factor is based on free imagination and the analyst's own personal opinion, not on facts, because there are no facts about what the future looks like. Analysts with low price targets will defend their key values for Lilly and Novo respectively by arguing that they do not believe Novo will grow in the next couple of years (at least not next year), and therefore the key factor must be much lower for Novo than for Lilly, but we all know how much sentiment in the stock market matters, and it only takes a small shift in sentiment for prices to move quite dramatically. I still hold my Novo shares.
    25 min sitten
    ·
    25 min sitten
    ·
    Fundamentally, analysts' price targets mean nothing; the 'real' numbers will eventually come to light, so one doesn't need to be so nervous about whether they are right or wrong. If one reads along here, one quickly gets the impression that analysts are some of the most fact-resistant, incompetent, and manipulative people there are.
    12 min sitten · Muokattu
    ·
    12 min sitten · Muokattu
    ·
    Novo itself has enormous problems getting its guidance right. The last couple of times, the market has downgraded Novo's guidance before the company itself did. A little worrying. Analysts are actually fantastically competent, here, given what their targets are.
  • 51 min sitten
    ·
    51 min sitten
    ·
    Have you sold at a loss for tax deduction? The rest of us want to go north.
    8 min sitten · Muokattu
    ·
    8 min sitten · Muokattu
    ·
    That sounds great with deductions! You get no deduction, you merely stand in minus with SKAT until you are again in plus and have a surplus.
    7 min sitten
    ·
    7 min sitten
    ·
    It is also a deduction. Even the tax authority's website calls it a “deduction for loss on shares”.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

DenmarkNasdaq Copenhagen
Määrä
Osto
227
Myynti
Määrä
401

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
168--
68--
69--
168--
51--
Ylin
312,85
VWAP
310,57
Alin
307,8
VaihtoMäärä
341 1 098 109
VWAP
310,57
Ylin
312,85
Alin
307,8
VaihtoMäärä
341 1 098 109

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Ostaneet eniten

Ostaneet eniten
VälittäjäOstettuMyytyNettoSisäinen
Anonyymi1 161 7641 161 76400

Myyneet eniten

Myyneet eniten
VälittäjäOstettuMyytyNettoSisäinen
Anonyymi1 161 7641 161 76400